A Natural Molecule Present in the Human Body Protects Against the Flu

Why It Matters

Dermcidin provides a natural, resistance‑resilient mechanism that could inspire next‑generation broad‑spectrum antivirals, reducing flu burden and potentially protecting against other respiratory viruses.

Key Takeaways

• Dermcidin binds influenza hemagglutinin, blocking cell entry
• Asymptomatic people have up to six‑fold higher dermcidin
• Peptide found in sweat, nose, saliva, and tears
• Targets conserved viral region, limiting resistance development
• Potential platform for broad‑spectrum respiratory antivirals

Pulse Analysis

The study led by the Fisabio Foundation reveals that dermcidin, a peptide long known for its antibacterial properties in sweat, also neutralizes influenza viruses. By attaching to the hemagglutinin protein at a highly conserved fusion site, dermcidin forces a structural shift that prevents the virus from merging with host cell membranes. Laboratory experiments in cell cultures and animal models confirmed that this interaction blocks infection before it can take hold. Notably, individuals who remained symptom‑free during flu season exhibited baseline dermcidin concentrations up to six times higher than those who fell ill.

This mode of action diverges sharply from existing antivirals, which mainly inhibit neuraminidase and are increasingly compromised by resistant strains. Because dermcidin targets a region of hemagglutinin that changes little across influenza subtypes, the peptide offers a built‑in safeguard against viral evolution. Researchers also detected the molecule in the nasopharynx, saliva, and tears—key entry points for respiratory pathogens—hinting at a natural, first‑line barrier that could be amplified pharmacologically. The concept of harnessing an endogenous peptide may extend to measles, common‑cold coronaviruses, and other airborne viruses.

Translating dermcidin into a therapeutic will require formulation work to preserve its activity and delivery to mucosal surfaces, but the payoff could be a broad‑spectrum antiviral with minimal resistance risk. Ongoing trials are probing whether synthetic analogs can boost the peptide’s stability while retaining its binding affinity. If successful, such agents could complement seasonal vaccines, reduce hospitalizations, and lower the economic toll of flu outbreaks. The discovery underscores the value of mining the human innate immune repertoire for next‑generation drug candidates.